Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atorvastatin + raltegravir refers to the concomitant administration of the HMG-CoA reductase inhibitor atorvastatin and the HIV integrase strand transfer inhibitor raltegravir. This combination was specifically evaluated in the AVIATOR study conducted by Radboud University Medical Center to assess pharmacokinetic drug-drug interactions in the context of treating hypercholesterolemia in patients with HIV infection. Atorvastatin is a standard-of-care statin used to lower LDL cholesterol and reduce cardiovascular risk, while raltegravir is an antiretroviral agent known for its favorable lipid profile. The Phase I study demonstrated that the two drugs do not have clinically significant pharmacokinetic interactions, allowing for their co-administration without dose adjustments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atorvastatin + raltegravir.